Elite in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Suzanne Lentzsch

Oncology | Hematology | Hematology Oncology
Trustees Of Columbia University In The City Of New York
622 W 168th St, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Trustees Of Columbia University In The City Of New York
622 W 168th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Suzanne Lentzsch is an Oncologist and a Hematologist in New York, New York. Dr. Lentzsch is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy.

Her clinical research consists of co-authoring 140 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Other, Biological
Study Drug: Isatuximab
Study Phase: Phase 2
Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Phase: Phase 1
Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab
Study Phase: Phase 1
Screening to Improve Survival in AL Amyloidosis
Screening to Improve Survival in AL Amyloidosis
Enrollment Status: Completed
Publish Date: October 28, 2024
Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis
A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis
Enrollment Status: Unknown
Publish Date: January 17, 2023
Intervention Type: Biological
Study Drug: Anti-CD38 Duostatin 5.2 Antibody Drug Conjugate
Study Phase: Phase 1/Phase 2
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Enrollment Status: Withdrawn
Publish Date: November 17, 2022
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone
Study Phase: Early Phase 1
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: August 01, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
Enrollment Status: Terminated
Publish Date: March 28, 2022
Intervention Type: Drug
Study Drugs: Melphalan-Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 1
View 12 Less Clinical Trials

138 Total Publications

Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies.
Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies.
Journal: Journal of clinical medicine
Published: May 14, 2025
Similar Doctors
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Alexander M. Lesokhin
Hematology Oncology | Hematology | Oncology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Alexander M. Lesokhin
Hematology Oncology | Hematology | Oncology

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (5.4 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexander Lesokhin is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Lesokhin is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Hamza Hashmi
Hematology | Transplant Surgery | Hematology Oncology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Hamza Hashmi
Hematology | Transplant Surgery | Hematology Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (5.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hamza Hashmi is a Hematologist and a Transplant Surgeon in New York, New York. Dr. Hashmi is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hashmi is currently accepting new patients.

Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Joshua R. Richter
Oncology | Hematology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Joshua R. Richter
Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (3.5 miles away)
212-731-7650
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Richter is an Oncologist and a Hematologist in New York, New York. Dr. Richter is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Secondary Immunodeficiency (SID), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lentzsch's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile